AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03817255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Substance use questionnaire
Description: Questions about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
Study NCT03817255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Questions about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
Study NCT03768531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).
Study NCT00095550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ
Description: Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
Study NCT00095550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan monotherapy
Description: Tablets, Oral, 150 mg, Once daily, 12 weeks.
Study NCT00095550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ monotherapy
Description: Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
Study NCT02737878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Study NCT01021722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified suture technique
Description: Both internal and external anal sphincter was sutured separately end to end
Study NCT03768531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabrilizumab
Description: Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks. (Cycle length 2 weeks).
Study NCT03445052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: XPAND
Description: The intervention is personalised to the psychosocial factors influencing poor photoprotection for each person. These factors could include beliefs that reduce motivation to protect as well as factors that prevent intentions being translated into action. The facilitator will use behaviour change techniques to target the factor most important for each person. Standardised content related to habit formation will be received. The intervention will be delivered via 7 1:1 sessions with a facilitator (psychologists or clinical nurse specialist). Sessions 1 (1.5 hours maximum) and 6 (45 minutes) will be delivered face to face in the home of the participant and the remaining sessions will be conducted via telephone calls or skype sessions.
Study NCT02857556 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Study NCT00840892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INTERdisciplinary COMmunity-based COPD management (INTERCOM)
Description: The INTERCOM program consisted of exercise training, education, nutritional therapy and smoking cessation support offered by local physiotherapists and dieticians in the proximity of the patient's home and by respiratory nurses in the hospital. The program was divided in a 4-month intensive intervention phase, followed by a 20-month maintenance phase.
Study NCT03375359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cfDNA screening
Description: cfDNA screening test for aneuploidy risk assessment
Study NCT04786041 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy
Description: laparoscopic appendectomy
Study NCT02266186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Cognitive behavioural therapy
Description: Therapist supported live therapy
Study NCT02266186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet based Cognitive behavioural therapy
Description: Internetbased CBTwith limited therapist support
Study NCT01508364 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY 43-9006)
Description: Dosage according to label or at discretion of the attending physician
Study NCT03487900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Colonoscopy
Description: Colonoscopy for CD patients in clinical remission
Study NCT04053452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve ultrasound
Description: Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.
Study NCT04053452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral nerve ultrasound
Description: Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.
Study NCT04053452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of strength
Description: Strength will be assessed by physical examination and recorded using Medical Research Council (MRC) scale, and a hand dynamometer will be used to measure grip strength.
Study NCT02857556 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Retinal photography:
Study NCT02857556 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dialyse
Study NCT02737878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance and Tone Training
Description: Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Study NCT00350402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle strength training
Description: The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
Study NCT00350402 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Respiratory muscle strength training
Description: The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
Study NCT00809965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg
Description: One tablet twice daily
Study NCT00809965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Description: One tablet twice daily
Study NCT02737878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance and Tone Training
Description: Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Study NCT00809965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet twice daily
Study NCT01130558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Management
Description: Using electronic insulin order template for basal-bolus insulin and education
Study NCT00809965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Study NCT03572023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrative characterization of MINOCA patients
Description: Characterization of MINOCA patients will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests.
Study NCT03572023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Characterization of MI patients with coronary obstruction
Description: Characterization of patients with myocardial infarction and obstructive atherosclerosis will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests.
Study NCT03330418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Starting with the forty-ninth dose,the trial went into the open phase. All participants were treated with the test drugs.
Study NCT03330418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160 mg
Description: In the Phase B,the researchers can adjust the dose of RC18 according to the subjects' willingness and recurrence, but the maximum dose of single dose should not exceed 320g.
Study NCT00809965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Study NCT02032355 — intervention group
Intervention type: PROCEDURE
Intervention: spinal anesthesia
Study NCT01477814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician chart reminder
Description: Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening
Study NCT01477814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: chart reminder, educational mat'ls, FIT
Description: Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet
Study NCT01477814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CR,ed mat'ls, FIT, phone call
Description: Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet. Subjects will also receive a telephone call from project staff to assess barriers to screening and to encourage CRC screening
Study NCT05271136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-aging Serum
Description: Serum composed of a patent-pending botanical extract, bioavailable peptides, antioxidants, post-biotics, and short and long-term moisturizers
Study NCT05271136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Moisturizer
Description: Anti-aging facial moisturizer to be used by study participants after serum
Study NCT05271136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cleansing Lotion
Description: Facial cleansing lotion to be used by study participants
Study NCT05271136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen to be applied after application of serum in the morning. Participants were asked to reapply every 2 hours
Study NCT04076033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional compressive bandage
Description: The functional compressive bandage is being performed with the volunteer sitting with the upper limb homolateral to the surgery supported by a support. After hydration of the limb, a cotton mesh is being used to prevent friction of the 1 cm density foam band being wrapped around the limb. No therapeutic procedure is being performed prior to functional compressive bandage.~The bandage of the limb is being performed with 5 cm, 10 cm, 15 cm elastic cotton bandages from the fingers to the axillary region in four layers.
Study NCT02743962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Wand
Description: The therapeutic wand will be used to apply a gentle caudad pressure on the pelvic floor, encouraging a release and gentle stretch of the muscles. The participants will follow a protocol of sweeping gently along one side then the other to find tender or tight areas, and then to apply the wand to relax and stretch the muscles for up to 5 minutes in total, twice weekly for the duration of the study.
Study NCT02743962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy control
Description: This group will receive standard specialist physiotherapy intervention for bladder pain syndrome as stated in the arm descriptor, and will not use the therapeutic wand.
Study NCT00166166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetraethylammonium (TEA)
Description: 5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min
Study NCT00166166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NG-monomethyl Arginine (L-NMMA)
Description: 5 minute intra-arterial infusion of L-NMMA 8 μmol/min
Study NCT00166166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradykinin
Description: Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.
Study NCT00166166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Description: Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.
Study NCT00166166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
Study NCT00166166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min
Study NCT00166166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
Study NCT01663519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Custom made insoles 35 shore
Description: Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
Study NCT01663519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prefabricated insoles
Description: Prefabricated insoles
Study NCT01663519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 55 shore Custom made insole
Description: Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
Study NCT02692105 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low dose rate prostate brachytherapy
Description: Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
Study NCT02692105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose Rate prostate brachytherapy
Description: Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
Study NCT03699293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib 200mg capsule
Description: celecoxib 200mg twice a day for 4 weeks
Study NCT03699293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen sodium 550mg tablet
Description: naproxen sodium 550mg twice a day for 4 weeks
Study NCT03699293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81mg tablet
Description: 81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period
Study NCT00149838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prefrontal rTMS
Description: Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
Study NCT00149838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Regimen
Description: Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
Study NCT00149838 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Stimulation
Description: The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
Study NCT02886637 — intervention group
Intervention type: OTHER
Intervention: None intervention
Study NCT00345761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
Study NCT00345761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
Study NCT00345761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
Study NCT04951518 — intervention group
Intervention type: OTHER
Intervention: VAN Stroke Scale
Description: V.A.N Stroke Assessment measures unilateral weakness with visual deficits, aphasia, and neglect in possible stroke patients
Study NCT00552552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue Patient Education Program (FIBS)
Description: 6 weekly sessions, 90 min each
Study NCT00552552 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fatigue Patient Education Program (FIBS)
Description: Participation in the program after the second follow-up
Study NCT03309579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberal RBC Transfusion Strategy
Description: RBC transfusion is triggered by a Hemoglobin value of ≤100g/L
Study NCT03309579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive RBC Transfusion Strategy
Description: Optional RBC transfusion is triggered by a Hemoglobin value of ≤80g/L
Study NCT00499044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDR Computerized Cognitive Assessment System
Description: Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
Study NCT00499044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MATRICS Consensus Cognitive Battery
Description: The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
Study NCT05271136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen to be applied after application of facial moisturizer in the morning. Participants were asked to reapply every 2 hours
Study NCT03676166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Inhaled cannabis
Study NCT03510611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib with fed or fasting
Description: The two groups of subjects were given an equal dose of Ensartinib capsules (225 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of Ensartinib.
Study NCT03685942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active light therapy (LUMINETTE®)
Description: light therapy on a portable light visor device
Study NCT03685942 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo light therapy
Description: placebo portable light visor device
Study NCT02037529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV
Study NCT02037529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02037529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02037529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03866109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temferon
Description: Genetically modified HSPCs
Study NCT02264639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor